Levoleucovorin
Gastroenteropancreatic Neuroendocrine Tumor
Hospices Civils de LyonPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Gastroenteropancreatic Neuroendocrine Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide National Cancer Institute (NCI) | Phase 4 | BBB |
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | B |
Lanreotide RayzeBio, Inc. | Phase 3 | B |
Everolimus RayzeBio, Inc. | Phase 3 | B |
Zimberelimab Hospices Civils de Lyon | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Levoleucovorin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →